Bladder Cancer Coverage from Every Angle

Enrique Grande, MD, on the Final Analysis of IMvigor130: Atezolizumab-Based Treatment of Metastatic Urothelial Carcinoma

Posted: Sunday, June 4, 2023

Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical implications of the final analysis of data from the IMvigor130 trial, which focused on the use of atezolizumab plus a platinum and gemcitabine in patients with metastatic urothelial carcinoma. She also explores the differences between the chemotherapy agents used (carboplatin and cisplatin) in this patient population.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.